Le Lézard
Classified in: Health, Business
Subjects: CON, LIC

Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company

TURKU, Finland, Dec. 11, 2019 /PRNewswire/ -- Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

Forendo Pharma has world leading experience in drug discovery and development of inhibitors of the HSD17B (17-beta-hydroxysteroid dehydregonase) enzyme family. These enzymes demonstrate significant potential in multiple disease areas beyond Forendo's own women's health focused programs. This is a diverse family of enzymes that regulate hormone action in specific tissues and where Forendo, together with its' close academic collaborators, has its core competence and leading experience. Forendo's lead program, HSD17B1 inhibitor FOR-6219, targeted for endometriosis, is in phase 1b clinical studies.

Risto Lammintausta, CEO of Forendo Pharma, said: "This agreement with Novartis is a significant recognition of Forendo's core capabilities and the vast future potential of this enzyme family in medicine, in multiple disease areas in addition to women's health. We are very pleased to enter this collaboration with Novartis and look forward to the results of our work together in the coming years." 

Under the terms of the agreement, Forendo will receive an upfront payment and equity investment from Novartis. Furthermore, Forendo's research activities under the collaboration will be funded by Novartis. After the term of the research collaboration, Novartis will assume responsibility for all future development, manufacturing and commercialization of the novel compounds. Forendo is also eligible to earn milestone payments, upon specified development, regulatory and commercial milestones and tiered royalties on the sales. Further details on the deal financials are not disclosed.

About Forendo Pharma

Forendo Pharma is a privately held drug development company, with core competences in modulating tissue specific hormone mechanisms. The company was founded in 2013 by leading academic endocrinology experts and Finnish drug development pioneers. Forendo is supported by strong international investors: Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures, Vesalius Biocapital III Partners and Sunstone Life Science Ventures. The company's pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; HSD17B5 inhibitor (discovery) for the treatment of polycystic ovary syndrome (PCOS); and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. Further information is available at www.forendo.com.

SOURCE Forendo Pharma

These press releases may also interest you

at 13:19
The Prime Minister, Justin Trudeau, today announced that the Interim President of Venezuela, Juan Guaidó, will visit Canada on January 27. The two leaders will discuss the importance of democracy and the need to respect the Venezuelan Constitution....

at 11:10
Buying a brand new car is one of the best feelings a driver can experience. But for some unlucky drivers, that feeling of joy doesn't last that much. If a policyholder's vehicle gets totaled in an accident, or it gets stolen the insurance company...

at 10:10
Compare-autoinsurance.org has launched a new blog post that explains why it is important to compare online car insurance quotes. For more info and free online quotes, please visit...

at 10:00
Does your office have a place to practice your golf stroke or grab a couple of lagers with coworkers? NuvoDesk Coworking does, plus much more. NuvoDesk is changing the way freelancers, entrepreneurs, and professionals work and encourage the public to...

at 09:10
To make sure their car insurance rates are still competitive, drivers are recommended to check the car insurance market at least twice per year. Insurance rates change frequently and different factors can lead to cheaper or more expensive premiums....

at 09:00
AlphaCredit©, a Latin American-focused FinTech platform that specializes in consumer lending and financial solutions for SMEs, has signed an equity round for up to USD$125 million led by SoftBank's Latin America Fund, one of the leading technology...

News published on 11 december 2019 at 03:00 and distributed by: